文献速递肿瘤 PET/CT

靶向Trop2的纳米抗体示踪剂用于实体瘤免疫PET显像

ImmunoPET imaging of Trop2 expression in solid tumors with nanobody tracers.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2023-10-04

本研究构建了两种靶向Trop2的纳米抗体免疫PET探针[68Ga]Ga-NOTA-RTD98和[68Ga]Ga-NOTA-RTD01,在临床前胰腺癌和胃癌模型中评估显像能力。结果显示[68Ga]Ga-NOTA-RTD98可清晰勾勒皮下肿瘤,优于[18F]-FDG或非特异性探针[68Ga]Ga-NOTA-RTD161;[68Ga]Ga-NOTA-RTD01具有改善的药代动力学和更优诊断能力。作者认为这两种示踪剂可能有助于通过无创显示靶点表达动态来更好地使用Trop2靶向治疗。

要点

  • Trop2在胰腺癌组织中的表达显著高于癌旁组织,单细胞测序显示其在胰腺导管细胞和腺泡细胞高表达。
  • [68Ga]Ga-NOTA-RTD98在细胞来源胰腺癌和患者来源胃癌模型中清晰显示皮下肿瘤,优于[18F]-FDG或非特异性探针。
  • [68Ga]Ga-NOTA-RTD01具有改善的药代动力学,在临床前胰腺癌模型中显示更优诊断能力。

核心结论

  • 作者报道了两种靶向人Trop2的纳米抗体示踪剂,可能有助于通过无创显示靶点表达动态来更好地使用Trop2靶向治疗。

研究设计与样本

  • 临床前研究:通过单细胞测序和組織微陣列(TMA)免疫组化检测胰腺癌Trop2表达,流式细胞术筛选胰腺癌细胞系Trop2表达。
  • 开发两种靶向Trop2的纳米抗体RTD98和RTD01,用镓-68(68Ga,T1/2=1.1 h)标记构建免疫PET探针。
  • 在表达不同水平Trop2的细胞来源胰腺癌模型和患者来源胃癌模型中研究示踪剂。

主要发现

  • 单细胞测序显示Trop2在胰腺导管细胞及腺泡细胞高表达;TMA免疫组化显示胰腺癌组织Trop2表达显著高于癌旁组织。
  • [68Ga]Ga-NOTA-RTD98免疫PET在细胞来源胰腺癌模型和患者来源胃癌模型中清晰勾勒皮下肿瘤,优于[18F]-FDG或非特异性探针[68Ga]Ga-NOTA-RTD161显像。
  • [68Ga]Ga-NOTA-RTD01具有改善的药代动力学,在临床前胰腺癌模型中显示更优诊断能力。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The high expression of the transmembrane glycoprotein trophoblast cell-surface antigen 2 (Trop2) was strongly associated with the progression of solid tumors, including pancreatic and gastric cancers. Our study aimed to construct Trop2-specific immuno-positron emission tomography (immunoPET) probes and assess the diagnostic abilities in preclinical pancreatic and gastric cancer models. METHODS: The expression of Trop2 in pancreatic cancer was determined by single-cell sequencing and immunohistochemistry on tissue microarray (TMA). Flow cytometry was used to screen the expression of Trop2 in pancreatic cancer cell lines. Two nanobodies (i.e., RTD98 and RTD01) targeting Trop2 were developed and labeled with gallium-68 (68Ga, T1/2 = 1.1 h) to construct immunoPET imaging probes. The agents were researched in cell-derived pancreatic and patient-derived gastric cancer models expressing varying Trop2. RESULTS: Single-cell sequencing results showed high expression of Trop2 in pancreatic ductal cells as well as acinar cells and immunohistochemical staining of TMA from pancreatic cancers showed significantly higher expression of Trop2 in cancerous than in paracancerous tissues. ImmunoPET utilizing [68Ga]Ga-NOTA-RTD98 could clearly delineate subcutaneous tumors, both in cell-derived pancreatic cancer models and patient-derived gastric cancer models, superior to imaging using [18F]-FDG or a non-specific probe [68Ga]Ga-NOTA-RTD161. Another probe with improved pharmacokinetics targeting Trop2, [68Ga]Ga-NOTA-RTD01, was further prepared and showed advantageous diagnostic capabilities in preclinical pancreatic cancer models. CONCLUSION: In the work, we reported two nanobody tracers targeting human Trop2 which may facilitate better use of Trop2-targeted therapeutics by noninvasively displaying expression dynamics of the target.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Huang W, Liang C, Zhang Y, et al. ImmunoPET imaging of Trop2 expression in solid tumors with nanobody tracers. Eur J Nucl Med Mol Imaging. 2023. PMID: 37792026. doi:10.1007/s00259-023-06454-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。